Sacheerome: What Is Its Niche and How Is It Planning to Turn It Into a Larger Business?
India’s fragrance and flavour industry plays an important role across personal care, home care, food and beverages. Sacheerome has built a niche in customised fragrance and flavour formulations, and its existing manufacturing capacity is already operating above rated levels. The company is now investing Rs.184 Cr in a new facility at YEIDA, which is expected to increase annual production capacity from around 7.6 lakh kg to 27.6 lakh kg, or nearly 3.6 times the current level.
With a market capitalization of Rs. 1,129.83 crore, the shares of Sacheerome Ltd were trading at Rs. 505 per share, up 1.07 percent from its previous closing price of Rs. 499.65 apiece. The stock trades at a P/E of 39.30x.
What Does Sacheerome Actually Do?
Sacheerome develops customised fragrances and flavours for a wide range of applications, including personal care, home care, fabric care, food, beverages, bakery, dairy and confectionery. The company says it has developed more than 10,000 products and serves customers across 30 countries. Its R&D capabilities are central to the business because fragrance and flavour formulations often need to be customised according to a customer's product, target market and application.
Also Read: Can Mahindra Lifespaces’ ₹1,100 Cr Cash and Strong Pre-Sales Support Bigger Bets?
This gives Sacheerome a relatively specialised position within the broader fragrance and flavour market. The more important issue, however, is whether that niche can support significantly larger volumes.
Revenue Has Already Been Growing Rapidly
Sacheerome's revenue from operations increased from Rs.63.88 Cr in FY22 to Rs.152.39 Cr in FY26. That represents a CAGR of roughly 24.3%. EBITDA rose 73.3% to Rs.40.66 Cr. EBITDA margin expanded by around 400 basis points to 26.02%.
PAT increased 78% to Rs.28.44 Cr, giving the company a PAT margin of roughly 18.2%. The important point is that this growth has occurred even though the company is operating with significant capacity constraints.
The Existing Plant Is Already Running Above Rated Capacity
Sacheerome's existing manufacturing facility operated at roughly 124% utilisation in FY26. Management has indicated that capacity constraints have prevented the company from fully addressing demand in some categories. That makes the new facility more than a simple capacity-expansion exercise. It is also intended to unlock demand that the company is currently unable to serve.
The existing annual production capacity is around 7.6 lakh kg. The new YEIDA facility is expected to take total capacity to approximately 27.6 lakh kg. That is an addition of about 20 lakh kg of capacity and would increase the manufacturing platform by nearly 3.6 times. The challenge is that the economics of a plant running above 120% utilisation are very different from those of a much larger plant that is still ramping up.
The Rs.184 Cr Expansion Is the Core of the Story
Sacheerome is investing Rs.184 Cr in its new YEIDA facility. As of March 2026, the company had invested approximately Rs.76.59 Cr, including Rs.28.79 Cr from IPO proceeds and Rs.47.80 Cr from internal accruals. Management has indicated that around Rs.60 Cr of debt could be used to fund part of the remaining requirement.
The new facility spans roughly 21,023 square metres and is intended to house fragrance and flavour manufacturing along with R&D, quality, application and consumer-evaluation infrastructure. The original indication was that production would begin around Q4 FY26, while subsequent management commentary around August 2026 pointed to commercial operations at the new facility. This makes FY27 the first meaningful period in which investors can begin assessing whether the expanded platform is translating into incremental revenue.
How Much Revenue Can the New Plant Add?
Management has estimated that the new facility could generate incremental revenue of around Rs.40–50 Cr in FY27. Cumulatively, management has indicated potential incremental revenue of around Rs.100 Cr by FY28.
These numbers are important because the Rs.184 Cr investment needs substantial utilisation to generate attractive returns. Management is targeting revenue of Rs.200 Cr in FY27, Rs.250 Cr in FY28 and Rs.300 Cr in FY29, compared with Rs.152.39 Cr in FY26.
Achieving Rs.300 Cr would mean almost doubling revenue from the FY26 base, implying a CAGR of roughly 25.3% over the three-year period. The implied annual growth rates are around 31% in FY27, 25% in FY28 and 20% in FY29. These are management targets, not forecasts, so the key issue is how quickly actual revenue moves toward them.
Fragrances Still Dominate, but Flavours Could Become an Important Growth Area
Sacheerome's business is currently heavily skewed toward fragrances. In FY26, fragrances accounted for roughly 94% of revenue, while flavours contributed around 6%. The company also generated approximately 94% of its revenue domestically, with exports accounting for around 6%
During H1 FY26, fragrance revenue was approximately Rs.75 Cr, while flavours contributed around Rs.1.46 Cr. The new facility includes dedicated infrastructure for flavours, creating an opportunity to diversify the revenue mix over time.
That diversification could matter because the company would have additional applications and customer categories to target as its manufacturing capacity expands. However, the flavour business is still relatively small, so investors should look for evidence that it is becoming commercially meaningful rather than assuming that the new infrastructure will automatically create a second growth engine.
The Margin Question Becomes More Important After Expansion
Sacheerome's FY26 EBITDA margin of 26.02% was supported partly by very high utilisation of the existing manufacturing base. That creates an important question for the expansion phase.
A new facility initially operates at lower utilisation, while depreciation, employee costs and other operating expenses begin increasing. As a result, the company may not immediately replicate the margins achieved at its existing plant.Management has indicated an EBITDA margin target of around 25%.
At that margin, the arithmetic would imply approximately Rs.50 Cr of EBITDA on Rs.200 Cr revenue in FY27, Rs.62.5 Cr on Rs.250 Cr revenue in FY28 and Rs.75 Cr on Rs.300 Cr revenue in FY29. These figures are only illustrative calculations based on the stated margin assumption. Actual EBITDA would depend on product mix, utilisation, operating costs, depreciation and financing expenses.
The key issue is therefore not simply whether revenue reaches Rs.300 Cr. It is whether the company can reach that level while maintaining a healthy return on the significantly larger capital base.
What Could Drive the Next Phase of Growth?
There are several potential drivers. First, capacity availability. The existing facility is already operating above rated capacity, so the new plant should give Sacheerome additional room to serve existing and new customers.
Second, customer expansion. Additional manufacturing capacity can allow the company to pursue larger contracts and enter categories that were previously constrained by production limitations.
Third, flavours. The relatively small contribution from flavours leaves room for the category to become a larger part of the business. Fourth, exports. Exports represented only about 6% of FY26 revenue, or approximately Rs.9.5 Cr, compared with around Rs.8 Cr in FY25. Management has identified the Middle East and GCC markets as areas of focus.
The opportunity is therefore not dependent on a single product category. It depends on whether Sacheerome can use the new manufacturing platform to broaden its customer base, applications and geographic reach.
Also Read: VA Tech Wabag’s ₹19,400 Cr Order Book: Is Growth Becoming More Working-Capital Intensive?
What Should Investors Track?
The next few years should provide clearer evidence on whether the expansion is working. The first metric is revenue growth. Management is targeting Rs.200 Cr in FY27 and Rs.300 Cr in FY29.
The second is YEIDA capacity utilisation. The new facility needs to move from initial ramp-up toward commercially meaningful utilisation. The third is EBITDA margin. Management is targeting around 25%, compared with 26.02% in FY26.
The fourth is flavour revenue. A rising contribution would indicate that the new facility is helping diversify the business. The fifth is exports. International revenue remains relatively small, so sustained growth here could provide another source of expansion. Finally, investors should track whether earnings and cash generation grow sufficiently to justify the Rs.184 Cr capital investment.